伊立替康联合替吉奥、雷替曲塞或氟尿嘧啶治疗进展期胃癌的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 伊立替康联合替吉奥、雷替曲塞或氟尿嘧啶治疗进展期胃癌的临床观察
TITLE:
摘要: 目的:观察伊立替康联合替吉奥、雷替曲塞或氟尿嘧啶治疗进展期胃癌的临床疗效和安全性。方法:选取2013年5月—2016年5月我院收治的一线方案治疗失败的进展期胃癌患者100例为研究对象。按照随机数字表法分为观察组(n=32)、对照A组(n=33)和对照B组(n=35)。观察组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+替吉奥胶囊60 mg/m2,po,bid(餐后)治疗,2周为1个周期;对照A组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+注射用雷替曲塞3 mg/m2,ivgtt(d1,15 min),3周为1个周期;对照B组患者给予盐酸伊立替康注射液180 mg/m2,ivgtt(d1)+亚叶酸钙注射液200 mg/m2,ivgtt(d1)+氟尿嘧啶注射液400 mg/m2,iv+2 400~3 000 mg/m2, ivgtt(46 h),d1,2周为1个周期。观察组和对照A组患者均治疗2个周期,之后第7天进行疗效评价;对照B组患者治疗3个周期,之后第12天进行疗效评价。观察3组患者临床疗效和不良反应发生情况。结果:对照A组患者脱落1例,对照B组患者脱落2例,最终纳入统计的合格病例数为97例,其中观察组32例、对照A组32例、对照B组33例。观察组患者的总缓解率(53.13%)明显高于对照A组(43.75%)和对照B组(36.36%),观察组患者的总控制率(81.25%)明显高于对照A组(68.75%)和对照B组(57.58%),差异均有统计学意义(P<0.05)。3组患者不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:伊立替康联合替吉奥治疗进展期胃癌患者的临床疗效较伊立替康联合雷替曲塞或氟尿嘧啶更好,且安全性较好。
ABSTRACT: OBJECTIVE: To observe clinical efficacy and safety of irinotecan combined with tegafur, raltitrexed or 5-fluorouracil for advanced gastric cancer. METHODS: One hundred advanced gastric cancer patients with first-line regimen failure were selected as research objects from our hospital during May 2013-May 2016. According to random number table, they were divided into observation group (n=32), control group A (n=33) and control group B (n=35). Observation group was given Irinotecan hydrochroride injection 180 mg/m2,ivgtt(d1)+Tegafur capsule 60 mg/m2,po, bid (after meal), 2 weeks as a cycle. Control group A was given Irinotecan hydrochroride injection 180 mg/m2,ivgtt(d1)+ Raltitrexed for injection 3 mg/m2,ivgtt(d1,15 min), 3 weeks as a cycle. Control group B was given Irinotecan hydrochroride injection 180 mg/m2,ivgtt(d1)+Calcium folinate injection 200 mg/m2,ivgtt(d1)+5-fluorouracil injection 400 mg/m2,iv+2 400~3 000 mg/m2, ivgtt(46 h),d1, 2 weeks as a cycle. On the 7th day after 2 courses of treatment, clinical efficacies of observation group and control group A were evaluated; on the 12th day after 3 courses of treatment, clinical efficacies of control group B were evaluated. Clinical efficacy and the occurrence of ADR were observed in 3 groups. RESULTS: One patient withdrew from control group A and 2 from control group B. 97 patients were included in the study finally, including 32 cases in observation group, 32 cases in control group A, 33 cases in control group B. The total remission rate of observation group (53.13%) was significantly higher than that of control group A (43.75%)and control group B (36.36%); total control rate of observation group (81.25%) was significantly higher than that of control group A (68.75%) and control group B (57.58%), with statistical significance (P<0.05).  There was no statistical significance in the incidence of ADR among 3 groups (P>0.05). CONCLUSIONS: Clinical efficacy of irinotecan combined with tegafur is better than irinotecan combined with raltitrexed or 5-fluorouracil in the treatment of advanced gastric cancer with good safety.
期刊: 2017年第28卷第11期
作者: 鲁赛红,夏韬
AUTHORS: LU Saihong,XIA Tao
关键字: 伊立替康;替吉奥;雷替曲塞;氟尿嘧啶;进展期胃癌;疗效;安全性
KEYWORDS: Irinotecan; Tegafur; Raltitrexed; 5-fluorouracil; Advanced gastric cancer; Therapeutic efficacy; Safety
阅读数: 583 次
本月下载数: 9 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!